{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:17Z","timestamp":1786979897620,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA015083"],"award-info":[{"award-number":["P30CA015083"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00262-020-02677-7","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T08:04:06Z","timestamp":1595318646000},"page":"215-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer"],"prefix":"10.1007","volume":"70","author":[{"given":"Jarrett J.","family":"Failing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"issue":"1","key":"2677_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihimaki","year":"2014","unstructured":"Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86(1):78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020","journal-title":"Lung Cancer"},{"issue":"4","key":"2677_CR2","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20(4):e300\u2013306. https:\/\/doi.org\/10.3747\/co.20.1481","journal-title":"Curr Oncol"},{"issue":"7","key":"2677_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14(7):1244\u20131254. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"2677_CR4","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1200\/JCO.2018.36.15_suppl.2009","volume":"36","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger HM (2018) Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. J Clin Oncol 36(15_suppl):2009\u20132009. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.2009","journal-title":"J Clin Oncol"},{"key":"2677_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32468","author":"JN Bodor","year":"2019","unstructured":"Bodor JN, Boumber Y, Borghaei H (2019) Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer. https:\/\/doi.org\/10.1002\/cncr.32468","journal-title":"Cancer"},{"issue":"10","key":"2677_CR6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27(10):1953\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdw289","journal-title":"Ann Oncol"},{"issue":"1","key":"2677_CR7","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41598-018-20622-8","volume":"8","author":"AS Mansfield","year":"2018","unstructured":"Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J (2018) Contraction of T cell richness in lung cancer brain metastases. Sci Rep 8(1):2171. https:\/\/doi.org\/10.1038\/s41598-018-20622-8","journal-title":"Sci Rep"},{"issue":"3","key":"2677_CR8","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.18632\/oncotarget.23469","volume":"9","author":"F Perea","year":"2018","unstructured":"Perea F, Sanchez-Palencia A, Gomez-Morales M, Bernal M, Concha A, Garcia MM, Gonzalez-Ramirez AR, Kerick M, Martin J, Garrido F, Ruiz-Cabello F, Aptsiauri N (2018) HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 9(3):4120\u20134133. https:\/\/doi.org\/10.18632\/oncotarget.23469","journal-title":"Oncotarget"},{"issue":"12","key":"2677_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K (2017) Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov 7(12):1420\u20131435. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0593","journal-title":"Cancer Discov"},{"key":"2677_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.coi.2018.03.006","volume":"51","author":"N Aptsiauri","year":"2018","unstructured":"Aptsiauri N, Ruiz-Cabello F, Garrido F (2018) The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses. Curr Opin Immunol 51:123\u2013132. https:\/\/doi.org\/10.1016\/j.coi.2018.03.006","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"2677_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, Consortium TR (2017) Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171(6):1259\u20131271 e1211. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02677-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02677-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T19:23:34Z","timestamp":1626809014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02677-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2677"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02677-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Mansfield reports research support from Novartis, and Verily; remuneration to his institution for participation on advisory boards for AbbVie, BMS, Astra Zeneca and Genentech; travel support from Roche, and is a nonremunerated director of the Mesothelioma Applied Research Foundation. Dr. Failing and Dr. Aubry report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Mayo Clinic\u2019s Institutional Review Board (IRB #13-007990).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}